Navigation Links
Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
Date:5/15/2012

and regulatory clearances even if successful will lead to product advancement or partnering; that that FDA or other regulatory clearances or other certifications, or other commercialization efforts will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that new collaborative partners will be found; that additional product opportunities will be established; or that that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®,
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 /CNW/ - On Aug. 20, at its annual ... Medical Association (CMA) voted on and approved a delegate ... medicinal cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed ... motion. The CMA is quite right to ... smoking any plant material, including medicinal cannabis. While some ...
(Date:8/22/2014)... , Aug. 22, 2014  Dr. Mark ... with the Diamond Lifetime Achievement Award in the field ... CEO of Cardiovascular Clinical Associates. Dr. Rasak ... managing all major aspects of the business; overseeing the ... as primary coronary intervention. In addition, he is an ...
(Date:8/22/2014)... Research and Markets has announced ... Catheter Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... WIRE)--May 24, 2007 - Inovio Biomedical,Corporation (AMEX:INO), ... for cancers and infectious diseases and a ... announced today,that interim clinical trial results demonstrated ... technology was,safe and tolerable, facilitated gene expression, ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 2Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 3Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 4Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 5
(Date:8/22/2014)... The regional economy is about to ... on the grow again. The plant will invest ... to boost production of the popular Highlander midsize sport ... investment to $4 billion. This step allows Toyota to ... flexibility to adjust its product mix to meet changing ...
(Date:8/22/2014)... News) -- Many Americans know little about how Ebola is ... outbreak in the United States, a new survey shows. ... there will be a major Ebola outbreak in the United ... family member will get sick with the deadly virus in ... Public Health poll. However, those opinions don,t match reality, ...
(Date:8/22/2014)... August 22, 2014 Beat Eczema ... they can use natural methods to completely cure the ... the attention of Shane Michaels, prompting an investigative review. ... affects the skin, it can still be extremely debilitating ... Michaels. “The intense itching and pain that it causes ...
(Date:8/22/2014)... (EGFR) mutations found in the circulating free tumor DNA ... cancer (NSCLC) patients correlates well with the EGFR mutations ... inhibitor (TKI) therapy is approved for EGFR activating mutation ... determining mutation status is with DNA derived directly from ... A more abundant and less invasive source of tumor ...
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3
... New studies at the University of Adelaide, Australia, will delve ... tumours and stroke. , The research, to be conducted in ... aim to find links between chemical signals in the brain ... , There are still many mysteries around how the brain ...
... Perfect" Score by the American Correctional Association Auditors ... Earns High Praise From Board Chair Romanowicz, ... an exhaustive,three-day audit and examination by the American Correctional ... pleased to report that the Donald W. Wyatt Detention,Facility ...
... Companies align,commercial and portfolio management employees by therapeutic ... of $10 to 20 billion, on average nine,marketing ... along,with approximately eight portfolio managers. At companies with ... three, commercial to,portfolio management staff, according to a ...
... and Other Ethnic Minorities at Increased Risk, BALTIMORE, ... J.,Barthelow Classen in The Open Endocrinology Journal shows a ... following the,discontinuation of a single vaccine, a vaccine to ... is a global epidemic of type 2,diabetes and metabolic ...
... are five-to-six times more likely to be at serious risk ... early as their teenage years, according to a new study ... Hill. , The findings, published Friday (April 4) in the ... children twice first while in grade school, then again ...
... at Ralphs Pharmacies Throughout Southern California, LOS ANGELES, ... pharmacy customers generic drugs for $4 per prescription at,its ... apply to hundreds of generic drugs prescribed for,30-day supplies ... stores,throughout Southern California. A list of the participating pharmacies ...
Cached Medicine News:Health News:Unlocking mysteries of brain cancer, stroke 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 3Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome 2Health News:Inactive kids face 6-fold risk of heart disease by teen years, study finds 2Health News:Ralphs Introduces $4 Generic Drugs 2
... on patented microplate agglutination technology. Its is ... donor ABO/Rh testing. PK7200 also handles weak ... antibody detection. The Automated Microplate System delivers ... proven reliability that for the past generation ...
... Tecan Haemotyper is an automated ... The Tecan Haemotyper combines a ... platform with the DiaMed agglutination ... process DiaMed-ID cards and microplates ...
... 1990s, the "Reversed" shoulder prosthesis has been ... success. More recently, an ever-growing number of ... to champion this prosthesis and the associated ... reversed technology is the result of nearly ...
Inquire...
Medicine Products: